Net Margin
Ucb SA

17.3%
Current
11%
Average
5.1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
17.3%
=
Net Income
1.1B
/
Revenue
6.2B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
BE
Ucb SA
XBRU:UCB
30.9B EUR
17%
US
Eli Lilly and Co
NYSE:LLY
725.7B USD
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
369.6B USD
24%
DK
Novo Nordisk A/S
CSE:NOVO B
2.2T DKK
35%
CH
Roche Holding AG
SIX:ROG
213.1B CHF
14%
CH
Novartis AG
SIX:NOVN
189.3B CHF
24%
UK
AstraZeneca PLC
LSE:AZN
165.7B GBP
14%
US
Merck & Co Inc
NYSE:MRK
195.3B USD
27%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
-126%
US
Pfizer Inc
NYSE:PFE
131.4B USD
13%

Ucb SA
Glance View

Market Cap
30.9B EUR
Industry
Pharmaceuticals

UCB SA, a Belgian multinational biopharmaceutical company, stands at the forefront of innovation in the medical field, committed to creating value by discovering new ways to treat severe diseases. Founded in 1928, UCB has transformed over the decades from its initial focus in chemicals to pioneering developments in advanced therapeutics targeting central nervous system disorders and immunology. Anchored by a robust research pipeline and a keen focus on rare diseases and specialty care, UCB has established a strong presence globally, reflecting its strategic pivot toward patient-centric approaches. With primary research facilities stationed in Braine-l'Alleud, Belgium, and Slough, UK, the company's scientific endeavors are bolstered by collaborations with research institutions worldwide, fostering an environment ripe for breakthrough discoveries. Financially, UCB's revenue streams are predominantly derived from its established portfolio of blockbuster drugs, such as Cimzia, Vimpat, and Keppra, which serve as critical lifelines for patients dealing with autoimmune diseases, epilepsy, and other chronic conditions. The company thrives on a dynamic business model that combines in-house scientific research with strategic partnerships and acquisitions to enhance its competitive edge. This synergy not only facilitates sustained growth in its core markets but also drives expansion into emerging ones, underscoring its global reach. By reinvesting substantial portions of its earnings into research and development, UCB ensures a steady pipeline of new products, thereby maintaining its stature in the highly competitive biopharmaceutical landscape. Through such strategic maneuvers, UCB aligns its operations with the overarching goal of delivering transformative therapies that improve the quality of life for patients around the world.

UCB Intrinsic Value
173.58 EUR
Undervaluation 6%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
17.3%
=
Net Income
1.1B
/
Revenue
6.2B
What is the Net Margin of Ucb SA?

Based on Ucb SA's most recent financial statements, the company has Net Margin of 17.3%.

Back to Top